Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346678 | 0.81 | GSK3B (0.67) | GSK3BALDH1A1 | |
| Hydrochloric Acid SCHEMBL29003046 | 0.79 | GSK3B (0.65) | GSK3BALDH1A1 | |
| SCHEMBL30449152 | 0.79 | GSK3B (0.52) | GSK3BP2RX7FDPSHDAC6FGFR1 | |
| SCHEMBL4797785 | 0.78 | HDAC6 (0.47) | HDAC6 | |
| SCHEMBL5106770 | 0.75 | P2RX7 (0.41) | GSK3BP2RX7FDPSHDAC6FGFR1 | |
| SCHEMBL1868819 | 0.72 | FDPS (0.44) | P2RX7FDPSHDAC6FGFR1FGFR4 | |
| SCHEMBL9073828 | 0.71 | FDPS (0.42) | GSK3BP2RX7FDPSHDAC6FGFR1 | |
| SCHEMBL17802570 | 0.71 | CFTR (0.61) | P2RX7FDPSHDAC6FGFR1FGFR4 | |
| SCHEMBL5281840 | 0.71 | FDPS (0.45) | P2RX7FDPSHDAC6FGFR1FGFR4 | |
| SCHEMBL23885424 | 0.70 | P2RX7 (0.66) | P2RX7FDPSHDAC6FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137202-B1 | PROCESS FOR THE SYNTHESIS OF IB-MECA | CAN-FITE BIOPHARMA LTD (IL) | 2017-06-21 | — | — | EP | disclosed |
| US-9102698-B2 | Process for the synthesis of IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-20100087636-A1 | PROCESS FOR THE SYNTHESIS OF IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2010-04-08 | — | — | US | disclosed |
| EP-2137202-A1 | PROCESS FOR THE SYNTHESIS OF IB-MECA | Can-Fite Biopharma Ltd. (IL) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008111082-A1 | PROCESS FOR THE SYNTHESIS OF IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087636-A1 | PROCESS FOR THE SYNTHESIS OF IB-MECA | ITPA, UMPS, CDA | GSK3B 3679/4885P2RX7 1756/4885FDPS 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.